||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Real-Time news about IS Pharma (London Stock Exchange): 0 recent articles
|dealit: It would seem from the statement that they could have issued more shares and raised even more capital. I would feel that share price will move north today on the back of solid set of results and that the market will love the placing over subscribed IMHO.|
|jdung: today company say: trade on line, ok.( ahead of last year..)
so the share price will go up side at future.|
|clogue: gogoneko: Thank you for your honesty regarding your holding, or lack of, in ISPH.
Logically it would be fair to say that you want the share price to fall, and I as a holder, would want the share price to rise.
Perhaps it would be better if people reading our posts keep our motives in mind.|
|carwhite: Nawh I will use it to buy an ISPH share.|
|boll: Actually results were quite good - Last year contained about US$1.2m of gains due to sale of North American rights for one of the drugs. Don't forget also the launch costs were high this year as the drugs launched in many European countries.
Two areas of concern
a.) Potential share issues or placings
b.) Staging of deferred payments for acquisitions.
Set against this the company is profitable and also the outlook is good over the next year so we should see further progress - I am surprised that the share price dipped.|
|dealit: Well I was wrong share price down, the only thing I can think is mm`s playing games with the share price they may have a large order to fill|
|dealit: Great set of results IMHO, share price should move north today.|
|gogoneko: Companies/Management in general can and will issue RNSs to give the impression of a better performance and what is actually taking place because they know a large portion (in terms of quantity of participants) of the investing population don't understand the intricacies of the accounting reports - I'm sure that nobody would deny that. What then happens is that donkey analysts and stock pimpers of various forms then quote the juicy bits in an attempt to build up the share price on weak foundations and the management don't have to keep an eye on a depressed share price which doesn't reflect well on them yet may be a true reflection of performance.|
When the right numbers appear in the results then I'll change my opinion, not before. The interims were disappointing, the progress of Variquel in the US was disappointing, and from what's happened recently in support of their strategy I think that the forthcoming prelims will be disappointing in terms of the expectations which the management have set.
There were quite a few wondering what the share price was doing in the high 50's recently but for me that range is justified (so yes, if you want to call it trying to talk the shares down) until the company demonstrates that it's returned to improving results as per their intentions and ambitions.
I'm expecting that it'll all turn out nice eventually (particularly when all the debt is eventually paid off) so that long-term holders are duly rewarded for their patience, but I don't assume that management is doing a great job behind the scenes when some of the numbers and actions indicate otherwise. I also consider having the price down below the recent placings as being a good thing for PIs as well as some compensation for the then discounted dilutions which took place to create ISPH.|
|gogoneko: "prudent book balancing"?! Throw-away sale of a profitable business as a desperate measure prior to year-end results accounting in order to flatter headline figures to boost the share price more like!
Where were the princely valuation techniques for Isoplex and Volplex which they applied in their earlier mates-rate acquisitions of SEPI AG and Acorus?|
IS Pharma share price data is direct from the London Stock Exchange